Turning a blind eye to anti-VEGF toxicities

Susan E. Quaggin*

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

36 Scopus citations

Abstract

Excessive blood vessel growth is a key feature of many retinal diseases, and recently, anti-VEGF therapy has been successfully applied to treat neovascular age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion. In this issue of the JCI, Kurihara et al. reveal an essential role of Vegfa in maintaining choroid vasculature and cone photoreceptors, critical for central and color vision. Their findings suggest that therapeutic approaches to blocking VEGF signaling in retinal diseases might have unexpected detrimental side effects and that the development of alternative strategies might be necessary.

Original languageEnglish (US)
Pages (from-to)3849-3851
Number of pages3
JournalJournal of Clinical Investigation
Volume122
Issue number11
DOIs
StatePublished - Nov 1 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Turning a blind eye to anti-VEGF toxicities'. Together they form a unique fingerprint.

Cite this